Esophageal Cancer – Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Esophageal Cancer – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
REQUEST A SAMPLE REPORT:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Buy this report via Credit Card/Paypal or Wire Transfer:
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
AMI Onco Theranostics LLC
AVEO Pharmaceuticals Inc
BioStar Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
Celldex Therapeutics Inc
Cristal Therapeutics BV
CSPC Pharmaceutical Group Limited
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
FLX Bio Inc
Guangzhou Saliai Stemcell Science and Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kura Oncology Inc
Leap Therapeutics Inc
LIfT BioSciences Ltd
Mebiopharm Co Ltd
Merck & Co Inc
Merrimack Pharmaceuticals Inc
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Moderna Therapeutics Inc
Omnitura Therapeutics Inc
Oncolys BioPharma Inc
OncoMed Pharmaceuticals Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pieris Pharmaceuticals Inc
Puma Biotechnology Inc
Revolution Medicines Inc
Rhizen Pharmaceuticals SA
Scancell Holdings Plc
Seattle Genetics Inc
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
Soricimed Biopharma Inc
Steba Biotech SA
Supratek Pharma Inc
Taiho Pharmaceutical Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Transgene Biotek Ltd
Tyg Oncology Ltd
XuanZhu Pharma Co Ltd
Ritesh Tiwari, Director